In vitro susceptibility of neisseria gonorrhoeae strains to mupirocin, an antibiotic reformulated for parenteral administration in nanoliposomes

Ahuva Cern*, Kristie L. Connolly, Ann E. Jerse, Yechezkel Barenholz

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

6 Scopus citations

Abstract

Neisseria gonorrhoeae is an urgent antibiotic-resistant threat. This study determined the MICs of mupirocin to be 0.0039 to 0.0625 μg/ml for 94 N. gonorrhoeae strains. Cross-resistance with other antibiotics was not detected. Mupirocin, which is currently limited to topical administration, demonstrated activity by injection when delivered in nanoliposomes. The nanoliposomal formulation of mupirocin is a potential treatment for drug-resistant N. gonorrhoeae.

Original languageAmerican English
Article numbere02377-17
JournalAntimicrobial Agents and Chemotherapy
Volume62
Issue number4
DOIs
StatePublished - Apr 2018

Bibliographical note

Publisher Copyright:
Copyright © 2018 American Society for Microbiology. All Rights Reserved.

Keywords

  • Antibiotic resistance
  • Antimicrobial activity
  • Antimicrobial resistance
  • Cross-resistance
  • Liposomes
  • Nano-mupirocin

Fingerprint

Dive into the research topics of 'In vitro susceptibility of neisseria gonorrhoeae strains to mupirocin, an antibiotic reformulated for parenteral administration in nanoliposomes'. Together they form a unique fingerprint.

Cite this